Glaukos (GKOS) Expected to Beat Earnings Estimates: Should You Buy?
Glaukos (GKOS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Retain Glaukos Stock in Your Portfolio Now
GKOS is positioned for growth as interventional glaucoma adoption expands, iDose and iStent synergies build, and scale drives operating leverage despite margin pressures.
Glaukos Corporation (GKOS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Glaukos Corporation (GKOS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Glaukos Corporation (GKOS) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Glaukos Corporation (GKOS) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Here's Why You Should Retain Glaukos Stock in Your Portfolio
GKOS gains momentum from iDose TR's strong launch and a growing pipeline, though reimbursement hurdles pose challenges ahead.
Glaukos (GKOS) Up 20% Since Last Earnings Report: Can It Continue?
Glaukos (GKOS) reported earnings 30 days ago. What's next for the stock?
Glaukos Corporation (GKOS) Presents at UBS Global Healthcare Conference 2025 Transcript
Glaukos Corporation ( GKOS ) UBS Global Healthcare Conference 2025 November 11, 2025 10:15 AM EST Company Participants Alex Thurman - Senior VP & CFO Christopher Lewis - Vice President of Investor Relations & Corporate Affairs Conference Call Participants Danielle Antalffy - UBS Investment Bank, Research Division Presentation Danielle Antalffy UBS Investment Bank, Research Division Good morning, everyone. Thank you so much for joining.
Here's What Key Metrics Tell Us About Glaukos (GKOS) Q3 Earnings
Although the revenue and EPS for Glaukos (GKOS) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
GKOS Stock Surges Following Q3 Earnings & Revenue Beat, Guidance Raised
Glaukos reported a narrower Q3 loss, strong 38% sales jump, and raised 2025 outlook as iDose TR and Epioxa fuel momentum across key franchises.
Glaukos Corporation (GKOS) Q3 2025 Earnings Call Transcript
Glaukos Corporation ( GKOS ) Q3 2025 Earnings Call October 29, 2025 4:30 PM EDT Company Participants Christopher Lewis - Vice President of Investor Relations & Corporate Affairs Thomas Burns - Chairman & CEO Joseph Gilliam - President & COO Conference Call Participants Thomas Stephan - Stifel, Nicolaus & Company, Incorporated, Research Division Adam Maeder - Piper Sandler & Co., Research Division Larry Biegelsen - Wells Fargo Securities, LLC, Research Division Ryan Zimmerman - BTIG, LLC, Research Division K. Gong - JPMorgan Chase & Co, Research Division David Roman - Goldman Sachs Group, Inc., Research Division Richard Newitter - Truist Securities, Inc., Research Division Mason Carrico - Stephens Inc., Research Division David Saxon - Needham & Company, LLC, Research Division Joanne Wuensch - Citigroup Inc., Research Division Michael Sarcone - Jefferies LLC, Research Division Anthony Petrone - Mizuho Securities USA LLC, Research Division Danielle Antalffy - UBS Investment Bank, Research Division Presentation Operator Ladies and gentlemen, thank you for standing by.
Glaukos (GKOS) Reports Q3 Loss, Tops Revenue Estimates
Glaukos (GKOS) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to a loss of $0.28 per share a year ago.
GKOS Stock Falls Despite Q2 Earnings & Revenues Beat, Guidance Raised
Glaukos' second-quarter results showcase a strong uptick in revenues. However, continued operating loss remains a cause of concern.
